Disappointing to see downward pressure like this on the SP at...

Disappointing to see downward pressure like this on the SP at this stage given how far the company have come. Also a shame to bid farewell to @RNClarke who has been a sound and informative contributor, all the best to you and thanks for the opinion you’ve provided.

It’s never pleasant to see your portfolio dwindling away but the story hasn’t changed. For reasons out of the control of the company, FDA approval will be delayed. Big deal. It fits with the initial goals and commercialisation strategy of the company in building a sustainable business model prior to expansion. It is also a rarity to see the company miss their deadline and once again it was out of their control.

Everyone has their own investment strategy and at the time being I’m certainly here for the long term based on just a few of the following;

- Philip Daffas. Creme de la creme.
- Tight ship.
- The product is superior to any currently available.
- Milestones are consistently achieved with no hype.
- The potential of the baby app is scary and at this point PCK could already be collecting solid revenues from the dementia app.

Just a few thoughts worth pondering and all IMO. Thanks for sharing correspondence with management also!